Sarepta Therapeutics Announces First Quarter 2015 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Needham & Company Awaits NDA Filing, Reit Buy on Sarepta Therapeutics (SRPT)
May 7, 2015 11:22 AM EDTNeedham & Company reiterate their Buy rating on Sarepta Therapeutics, Inc. (NASDAQ: SRPT) with the price target set $38 while awaiting the NDA filing and approval of Eteplirsen.
Needham & Company analyst, Chad Messer, commented on SRPT, saying, "A pre-NDA meeting with the FDA... More
Sarepta Therapeutics (SRPT) Misses Q1 EPS by 15c
May 7, 2015 7:47 AM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.15), $0.15 worse than the analyst estimate of ($1.00).
Sarepta said its pre-NDA meeting with the FDA remains calendared for second quarter 2015.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
... More